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ABSTRACT 
 
The disruption of myocardial extracellular matrix (ECM) has been implicated in 
myocardial dysfunction during sepsis. However, the underlying mechanism(s) are not 
clear. Interleukin-33 (IL-33) is a cytokine which regulates collagen synthesis in various 
cardiac pathologies. The purpose of the present study is to test whether IL-33 contributes 
to sepsis-induced myocardial dysfunction through regulation of matrix 
metalloproteinase-9 (MMP-9). The in vivo, feces-induced peritonitis (FIP) in mice and 
in vitro lipopolysaccharide (LPS) treatments to isolated cardiomyocytes were used. In 
FIP mice, myocardial IL-33 and MMP-9 expression were increased and myocardial 
contractility was decreased. Myocardial dysfunction in FIP mice was prevented when 
treated with soluble ST2 (sST2), a decoy receptor of IL-33. This study showed for the 
first time that inhibiting IL-33 prevented cardiac dysfunction and MMP-9 expression in 
septic mice. In vitro studies produced congruent results. Our results support that IL-33 
plays an important role in mediating sepsis-induced myocardial dysfunction. 
 
Keywords: sepsis; myocardial dysfunction; interleukin-33; ST2; matrix 
metalloproteinase-9; feces-induced peritonitis; lipopolysaccharide; cardiomyocytes 
 
 
  
iv 
 
DEDICATION 
 
I dedicate this thesis to my loving family who has been my constant source of 
inspiration and comfort. My mother’s persistent faith in me keeps me going every day 
and my father’s respect for education pushes me to be better. Without them I would not 
be here.  
  
v 
 
ACKNOWLEDGEMENTS 
 
I would like to thank my supervisors, Dr. Claudio Martin and Dr. Tao Rui. You 
have given me a tremendous opportunity to work in your lab and expand my skills as a 
researcher. Thank you for being patient with me while I was learning all the techniques 
in the laboratory. You were always there to help and encourage me to successfully 
complete my degree. Your detailed advice and guidance will not be forgotten.  
To Dr. Raymond Kao, I would like to thank you for providing positive feedback 
during lab meetings and sharing your passion for research to help brave men and women 
overseas. To Dr. Anagyros Xenocostas, for sharing your expertise and providing 
technical support. To Wendy Brown and Ben Hedley, for completing the blood 
count/differential. To other distinguished faculty members who served on my committee 
Dr. Karel Tyml, Dr. Barry Tepperman and Dr. Qingping Feng: Thank you for guiding 
me throughout the course of preparing for and conducting the research. Special thank 
you to Dr. Feng who kindly filled in as my GSR on a short notice and helped improve 
my manuscript. Special thank you to the Department of National Defense for funding 
this research. 
To my collegues and friends in the Rui lab: Thank you for your patience, 
company and friendship. Special thanks to Xuemei Xu, for generating the pressure-
volume loops in animal studies. 
Lastly to Dr. Jinchao Zhang, whom I first worked with in the laboratory and 
taught me many things as a mentor and a friend.  
 
 
  
vi 
 
TABLE OF CONTENTS                                                                                        PAGE 
 
 
 
CERTIFICATE OF EXAMINATION .............................................................................. ii 
ABSTRACT ...................................................................................................................... iii 
DEDICATION .................................................................................................................. iv 
ACKNOWLEDGEMENTS ................................................................................................v 
LIST OF FIGURES ........................................................................................................ viii 
LIST OF TABLES ............................................................................................................ ix 
LIST OF ABBREVIATIONS .............................................................................................x 
CHAPTER 1: INTRODUCTION 
1.1: Sepsis 
1.2: Sepsis-induced cardiac dysfunction 
1.3: Mechanisms of sepsis-induced cardiac dysfunction 
1.4: Lipopolysaccharide 
1.5: Myocardial extracellular matrix 
1.6: Interleukin-33 and ST2 
1.7: Matrix metalloproteinases 
1.7.1: MMP-9 and sepsis 
1.8: Animal sepsis models 
1.9: Purpose of study 
1.10: Hypothesis 
1.11: Objectives of Thesis 
2 
3 
4 
6 
9 
10 
12 
13 
14 
15 
16 
16 
 
 
CHAPTER 2: MATERIALS AND METHODS 
 
2.1: Animals 
2.2: Feces-induced peritonitis 
19 
19 
  
vii 
 
2.3: Measurement of cardiac function 
2.4: Hematological analysis 
2.5: Measurement of circulating factors 
2.6: Picrosirius staining of the heart tissue 
2.7: Primary neonatal mouse cardiomyocyte culture 
2.8: SDS-PAGE and Western blot 
2.9: Measurement of MMP-9 activity 
2.10: Statistical analysis 
19 
21 
22 
23 
24 
25 
26 
27 
 
 
CHAPTER 3: RESULTS 
 
3.1: Establishing murine sepsis model 
3.2: ST2 prevents cardiac dysfunction observed in FIP mice 
3.3: Collagen staining 
3.4: Expression of IL-33 and MMP-9 in FIP mice 
3.5: Myocardial MMP-9 in FIP mice using gelatin zymography 
3.6: Soluble ST2 prevents augmentation of MMP-9 expression in FIP     
           mice myocardium 
3.7: Endotoxin levels, comparison between in vivo and in vitro system 
3.8: LPS induces IL-33 expression in culture cardiomyocytes 
3.9: Cardiomyocytes secrete MMP-9 in response to LPS 
3.10: Soluble ST2 inhibits induction of MMP-9 in cardiomyocytes 
29 
32 
35 
36 
38 
40 
 
42 
44 
46 
48 
 
CHAPTER 4: DISCUSSION 
CHAPTER 5: FUTURE STUDIES 
REFERENCES 
CURRICULUM VITAE 
50 
60 
61 
72 
 
 
 
  
viii 
 
LIST OF FIGURES 
 
 
FIGURE DESCRIPTION PAGE 
Figure 1.1 Schematic diagram of proposed hypothesis 17 
Figure 3.1 Soluble ST2 prevents cardiac dysfunction caused by feces-
induced peritonitis 
34 
Figure 3.2 Collagen staining of FIP myocardium 35 
Figure 3.3 FIP leads to increased expression of myocardial IL-33 and 
MMP-9 
37 
Figure 3.4 FIP leads to increased expression of myocardial MMP-9 39 
Figure 3.5 ST2 prevents MMP-9 induction in FIP mice heart 41 
Figure 3.6 ST2 prevents MMP-9 induction in FIP mice heart 43 
Figure 3.7 LPS treatment increases IL-33 expression in 
cardiomyocytes 
45 
Figure 3.8 LPS treatment increases MMP-9 release from 
cardiomyocytes 
47 
Figure 3.9 Soluble ST2 inhibits LPS-induced MMP-9 release from 
cardiomyocytes 
49 
Figure 4.1 Schematic diagram of hypothetical mechanism in LPS/IL-
33 signaling pathway in cardiomyocyte 
58 
 
  
ix 
 
LIST OF TABLES 
 
 
TABLE DESCRIPTION PAGE 
Table 3.1 White blood cell differential and platelet count 30 
Table 3.2 Plasma concentration of lactate 31 
Table 3.3 In vivo hemodynamic measurements 33 
 
  
x 
 
LIST OF ABBREVIATIONS 
 
 
ANOVA Analysis of variance 
AP-1 Activator protein-1 
CD-14 Cluster of differentiation-14 
CLP Cecal ligation puncture 
CO Cardiac output 
CRP C-reactive protein 
dP/dt max Maximal rate of pressure rise 
dP/dt min Maximal rate of pressure decline 
ECM Extracellular matrix 
EF Ejection fraction 
ERK Extracellular signal-regulated kinase 
ESPVR End systolic pressure volume relationship 
FIP Feces –induced peritonitis 
HR Heart rate 
IFN Interferon 
IKK Inhibitor of NF-κB kinase 
IL-1β Interleukin-1β 
IL-1RAcP IL-1 receptor accessory protein 
IL-33 Interleukin-33 
IRAK Interleuin-1 receptor-associated kinase 
IRF3 IFN-regulatory factor 3 
JNK c-Jun N-terminal kinases 
LAL Limulus amebocyte lysate 
LBP LPS binding protein 
LPS Lipopolysaccharide 
LV Left ventricular 
LVEDP Left ventricular end diastolic pressure 
LVEF Left ventricular ejection fraction 
LVESP Left ventricular end systolic pressure 
MAL MyD88 adaptor-like 
MAP Mean arterial pressure 
MAPK Mitogen-activated protein kinase 
MD-2 Myeloid differentiation factor-2 
MMP-9 Matrix metalloproteinase-9 
MRI Magnetic resonance imaging 
MyD88 Myeloid differentiation factor 88 
NF-HEV Nuclear factor from high endothelial venules 
  
xi 
 
NF-kB Nuclear factor κB 
PAGE Polyacrylamide gel electrophoresis 
PAMP Pathogen-associated molecular patterns 
PBS Phosphate buffered saline 
PV Pressure-volume 
PVDF Polyvinylidene difluoride 
SDS Sodium dodecyl sulfate 
SEM Standard error of mean 
sST2 Soluble ST2 
ST2 Suppression of tumorigenicity 2 
ST2L Membrane bound ST2 
SV Stroke volume 
SVR Systemic vascular resistance 
SW Stroke work 
TIMP Tissue inhibitors of metalloproteinases 
TIR Toll/IL-1 receptor 
TIRAP TIR domain-containing adaptor protein 
TLR Toll-like receptors 
TNF- α Tumor necrosis factor-α 
TRAF6 TNF receptor-associated factor 6 
TRAM TRIF-related adaptor molecule 
TRIF TIR-domain-containing adapter-inducing interferon-β 
   
1 
 
 
 
 
 
 
 
 
 
 
CHAPTER 1: INTRODUCTION 
 
2 
 
 
Section 1.1: Sepsis 
Sepsis is the leading cause of mortality in the critically ill, with mortality rate as 
high as ~50% [1]. Despite continued advances in modern medicine, the incidence of 
sepsis and its mortality continue to rise. Epidemiological reports indicate that the 
incidence is increasing at rates between 1.5% to 8% every year [2]. 
Sepsis is a syndrome defined as a systemic inflammatory response to an infection. 
Infection can be triggered by bacteria, virus or fungi and its damage depends on the 
pathogen’s virulence and the resistance of the host to that pathogen. In the case of gram-
negative bacteria, various constituents of the cell wall determine its virulence including 
lipopolysaccharides (LPS), peptidoglycans, lipoproteins and fragellin. These molecules 
are known as pathogen-associated molecular patterns (PAMPs) and they are recognized 
by the host’s immune system [3]. The host’s initial reaction to an infection is local 
inflammation. First, the innate immune system attempts to eradicate the pathogen using 
physical barriers, inflammatory cells, proteases, cytokines and chemokines in co-
ordination with other components. Inability of the innate immune system to eradicate the 
pathogen can result in bacteria entering the bloodstream, thus becoming a systemic 
infection. The host’s exaggerated response to the inflammation is called sepsis. In the 
event of organ failure the term severe sepsis is used. As the disease progresses it may 
develop into septic shock where hypotension persists despite adequate fluid resuscitation. 
Gram-negative infections are responsible for a large proportion (38%) of septic cases [4]. 
The majority of cases of mortality in septic patients are from multiple-organ 
dysfunction rather than the initial infection [2]. Septic patients experiencing myocardial 
dysfunction have a much poorer prognosis than those without cardiac complications [5]. 
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A better understanding of causes and mechanism behind sepsis pathology is essential in 
developing effective intervention to improve patient prognosis. 
 
Section 1.2: Sepsis-induced Cardiac Dysfunction 
Cardiac dysfunction is observed in 40% to 50% of patients with sepsis where the 
ability of the heart to pump blood, or ejection fraction, is attenuated [6]. This reduction of 
ejection fraction is referred to as myocardial depression. Myocardial dysfunction involves 
both left and right ventricles, which greatly increases the mortality of septic patients [7].  
Initially cardiac dysfunction in sepsis was thought to exist in two phases. Patients 
undergoing “warm shock” exhibited hyperdynamic circulation with peripheral 
vasodilation and high cardiac output (CO) [8]. This was followed by “cold shock” with 
the characteristics of increased vascular tone and low CO [8]. With the introduction of 
pulmonary artery catheters which allowed accurate measurements of CO, it was found 
that septic patients who were adequately resuscitated, consistently demonstrated those 
characteristics of warm shock – low systemic vascular resistance and high CO [9], 
leading to the understanding that the haemodynamic profile of patients in “cold shock” 
was due to inadequate resuscitation.  Despite high CO seen in sepsis patients, many suffer 
from myocardial dysfunction. Common features include biventricular dilation, decreased 
contraction, reduced ventricular compliance, and reduced ejection fraction [7]. This 
dysfunction is reported to peak after a few days of sepsis onset and resolve within 7 to 10 
days in patients that survive [7].  
It has been well documented that cardiomyocytes experience contractile 
dysfunction under septic stimuli [10, 11]. Cardiomyocytes express Toll-like receptors 
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(TLRs) like those expressed on innate immune dendritic cells, which enables them to 
respond to danger signals and mediate local inflammatory responses [12]. Previous 
studies have shown a correlation between sepsis and alterations in myocardial structure 
[13, 14] but the underlying molecular mechanisms involving cardiomyocytes remain to 
be elucidated. 
 
Section 1.3: Mechanisms of sepsis-induced cardiac dysfunction 
One of the earliest theories behind myocardial dysfunction observed in sepsis was 
global myocardial ischemia. This has been disproven by several studies. Investigators 
explored this idea by using thermodilution coronary sinus catheters to measure coronary 
blood flows in septic patients. Their measurements showed normal or even elevated 
coronary blood flow in septic hearts compared to healthy controls [15]. There was also no 
elevation in myocardial lactate production, a key byproduct of anaerobic respiration [15]. 
Another group of investigators also verified these finding using the same methods [16]. 
These studies provide strong evidence that myocardial perfusion is not decreased during 
sepsis and thus is not a contributing factor to myocardial depression. 
 The idea of circulating substance causing cardiac dysfunction in sepsis originates 
back to 1947 in Wiggers’ report on myocardial depressant factors present in hemorrhagic 
shock [17]. In 1985 it was shown, for the first time, that the serum of septic patients with 
myocardial dysfunction exhibited myocardial depressant effects on isolated 
cardiomyocytes [18]. When cultured cardiomyocytes were treated with septic patients’ 
serum, it caused a significant depression in myocardial cell shortening in a concentration-
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dependent manner. The presence of myocardial depressant factors also correlated with 
higher mortality in sepsis patients [19].  
 Many different cytokines have been identified to make up the myocardial 
depressant substance which has been characterized as a water-soluble, heat stable, 10-25 
kDa protein. Out of the exhaustive list of potential mediators of myocardial depression, 
tumor necrosis factor-α (TNF-α) and Interleukin (IL)-1β have been shown to have a 
pivotal role in sepsis-induced myocardial dysfunction. Increased TNF-α levels in dogs 
produced effects similar to clinical septic shock such as hypotension, increased CO, 
peripheral vasodilation [20] and a reduction in ejection fraction [21]. Furthermore, in 
vitro systems using mammalian cardiomyocytes also exhibited decreased contractility 
when exposed to TNF-α [22]. Many promising results that pointed towards TNF-α being 
at the core of sepsis-induced myocardial dysfunction led to a hopeful, yet unsatisfactory, 
pilot study of administering anti-TNF-α monoclonal antibody to septic patients. Although 
the antibody improved left ventricular function, it did not alter the patients’ outcome [23].   
 IL-1β studies have produced similar results as TNF-α where it directly depressed 
cardiac contractility. Increased levels of IL-1β have been detected in human and animal 
models of sepsis [24]. Just as seen with TNF-α, in vitro treatment of IL-1β to cultured 
cardiomyocytes caused attenuation of the maximum extent and peak velocity of myocyte 
shortening [25]. However, using IL-1β antagonist in human septic shock patients failed to 
alter the overall mortality despite its beneficial effects on hemodynamic and metabolic 
parameters [26].  
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Section 1.4: Lipopolysaccharide 
Gram-negative bacteria infection accounts for large proportion of septic cases [4]. 
An important component of the gram-negative bacteria cell wall that is responsible for 
eliciting strong host immune response is LPS. Along with TNF-α and IL-1β, it is an 
important contributing factor of myocardial depression. The bacterial endotoxin, LPS, 
stimulates a strong inflammatory response by upregulating and promoting the release of 
pro-inflammatory cytokines. Many studies have indicated that LPS negatively influences 
cardiovascular function. In order to deduce the direct correlation between LPS and 
cardiovascular function, healthy human subjects were injected with a bolus dose of 
endotoxin. The investigators were able to observe similar hemodynamic characteristics of 
sepsis in the volunteers 3 hours after the injection, such as reduced systemic vascular 
resistance (SVR) [27]. They also observed in an in vitro system that LPS treatment 
directly decreased the extent of myocyte shortening [11].  
 
LPS is a glycolipid molecule that is comprised of three subregions: lipid A, the 
core, and the O-polysaccharide. Lipid A is the representative toxic element of LPS and is 
conserved across various strains of gram-negative bacteria. It is composed of β-D-
glucosaminyl-(1-6)-α-D-glucosamine disaccharide with two phosphoryl groups and 
acylated by four R-3-hydroxy fatty acid residues. The core consists of hetero-
oligosaccharide that is less variable between different bacterial species, as opposed to 
highly variable O-polysaccharide region. It is typically composed of heptose and 2-keto-
3-deoxyoctonic acid. The O-polysaccharide region has variable sugar composition with 
different number of repeating oligosaccharide units. Due to its variability, this region is 
responsible for serological specificity between different bacterial strains [28].  
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The Toll receptor was first discovered in Drosophila melanogaster and its role in 
innate immunity was recognized when those without the receptor were highly susceptible 
to fungi [29]. The mammal counterpart of Toll receptors, Toll-like receptors (TLR), was 
discovered in 1997 [30]. Since then, ten different TLR have been identified in humans 
[31] and twelve in mice [32]. TLRs can be classified based on their subcellular 
localization and their agonist. TLR-3, TLR-7, TLR-8 and TLR-9 are located in 
intracellular compartments and are sensitive to nucleic acid recognition, while TLR-1, 
TLR-2, TLR-4, TLR-5 and TLR-6 are typically found on the cell surface and specialize 
in detecting a variety of products present in bacteria, parasites and fungi such as 
glycolipids, lipopeptides and flagellin [33]. TLRs are classified as type-1 transmembrane 
receptors with extracellular leucin-rich repeat motifs and a conserved cytoplasmic 
Toll/IL-1 receptor (TIR) domain [34].  It was shown in 1998 that TLR-4 was the 
signaling receptor for LPS in a study that showed mice without TLR-4 lack responses to 
LPS [35]. 
Circulating LPS is bound to soluble LPS binding protein (LBP) which acts as an 
opsonin [36]. LPS-LBP is then accepted by cluster of differentiation (CD)-14 on the cell 
membrane, CD-14 mediates LPS binding to the TLR-4 and myeloid differentiation factor 
2 (MD-2) and initiate the cell signaling cascade. MD-2 is a co-receptor of TLR-4 and 
crucial in LPS induced signaling [37]. The lipid A portion of LPS interacts directly with 
the hydrophobic pocket in MD-2 and induces dimerization of TLR-4 receptors [38]. 
Subsequent to LPS binding to TLR-4-MD-2, two pathways are activated (early vs. 
delayed) depending on which TIR domain-containing adaptor molecules are recruited to 
TLR-4 through interaction with the TIR domain of TLR-4. The early response is 
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mediated by myeloid differentiation factor 88 (MyD88) and TIR domain-containing 
adaptor protein (TIRAP), also called MyD88 adaptor-like (MAL). This pathway leads to 
early activation of nuclear factor κB (NF-κB) which induces production of 
proinflammatory cytokines such as TNF-α. The delayed response is independent of 
MyD88 and signals via TIR-domain containing adaptor, which induces interferon β 
(TRIF) and TRIF-related adaptor molecule (TRAM).  This pathway leads to activation of 
interferon (IFN)-regulatory factor 3 (IRF3) and subsequently delayed activation of NF-
κB. This leads to production of IFN-β and IFN-inducible genes [39]. The NF-κB pathway 
has been reported in the past to be a key participant in decreased cardiomyocyte 
contractility and inflammatory response after TLR activation [11].  
LPS initiates numerous responses in the mammalian system including activation 
of the innate immune system, complement cascade and characteristic shock syndrome 
[40]. Its effects are secondary to LPS inducing the upregulation and release of 
inflammatory cytokines. Though macrophages are the primary targets of LPS [41], 
cardiomyocytes have also been reported to express TLR-4 receptor on their cell surface, 
thus they are capable of responding to LPS [11].  Numerous reports provide strong 
evidence that LPS has a detrimental effect on the heart including mediating vascular 
inflammation in atherosclerosis [42]. In chronic heart failure patients, increased LPS 
levels were detected in patient plasma [43]. Increased level of plasma LPS has also been 
measured from septic patients and thus has been implicated to be a crucial instigator of 
sepsis pathology [44]. Also when LPS was injected in low doses to healthy human 
volunteers, they exhibited similar hyperdynamic response seen in septic patients [44]. 
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Section 1.5: Myocardial Extracellular Matrix  
The collagen network is a crucial component of the heart’s extracellular matrix 
(ECM) where it works to secure and support cardiomyocytes in proper alignment 
required for coordinated contraction and it helps determine heart compliance. The ECM 
is mainly composed of collagen with smaller proportion contributed by elastin, laminin 
and fibronectin [45]. The major collagen type accounting for >50% is collagen type I, 
followed by collagen type III which comprises around 10% of the heart’s ECM [45]. The 
architectural complexity of the ECM was identified through the use of scanning election 
microscopy [46] where the highly organized network provided structural integrity 
between adjacent cardiomyocytes and coordination to overall myocyte shortening. The 
interstitial collagen in the myocardium is dependent upon a balance between synthesis 
and degradation. In normal myocardium, only about 2-4% of the myocardium is reported 
to be comprised of collagen. Yet, even small changes in collagen concentration have been 
shown to mediate drastic effects on the heart’s mechanical properties [45]. In addition to 
the quantity, the relative proportion, the diameter and the spatial alignment of collagens 
can all lead to alterations to this network, which can exert marked effects on the functions 
of the heart.  
The aberrant balance of collagen production and degradation was observed in 
patients with dilated cardiomyopathy where a 30-fold increase in collagenase activity has 
been reported [47]. Another study looked at isolated papillary muscle as well as felines 
with pressure overload-induced hypertrophy that were treated with plasmin to disrupt the 
ECM. Decreased systolic function, as well as decreased collagen content in the papillary 
muscles was observed [48]. In a landmark paper published by Parker showed that septic 
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patients exhibited decreased left ventricular ejection fraction (LVEF) and ventricular 
dilation which was reversible in 7 to 10 days in survivors [6]. This lead to subsequent 
studies that looked at myocardial ECM changes in sepsis and its potential mediators [49].  
 
Section 1.6: Interleukin-33 and ST2 
A relatively new cytokine implicated in heart collagen biology is interleukin (IL)-
33. IL-33 (also known as IL-1F11) was identified as a newest member of the IL-1 family 
in 2005 while looking for proteins with similar structure [50]. It has been identified in the 
past by different researchers as DVS27, a gene up-regulated in canine cerebral vasoplasm 
[51] and NF-HEV, nuclear factor from high endothelial venules [52]. The sequence of 
IL-33 has been mapped in both human chromosome 9 and mouse chromosome 19 which 
encodes for proteins consisting of 270 and 266 amino acids respectively [53]. IL-33 
shares a close amino acid homology to IL-18 and a β-sheet trefoil fold structure, 
characteristic of all IL-1 family members [53]. Functionally IL-33 appears to have dual 
actions as a traditional cytokine and also as an intracellular nuclear factor [53].  
IL-33 has been shown to be expressed in various tissue types including the heart. 
Initially it was thought that IL-33 needed to be cleaved by caspase-1 to be active, like IL-
1β [50]. However, recent papers have demonstrated that IL-33 is not a physiological 
substrate of caspase-1, as it lacks a classical caspase-1 cleavage site [54-56]. Furthermore, 
it was shown that full length IL-33 is able to exert its biological effects via its receptor 
without proteolytic processing [55]. 
ST2 (suppression of tumorigenicity 2) is a member of the Toll-like/IL-1 family of 
receptors [56]. This receptor for IL-33 has two forms: a membrane bound form (ST2L) 
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and a soluble form (sST2). The sST2, released alongside elevated IL-33 expression, acts 
as a negative feedback mechanism by acting as a decoy receptor. Upon binding of IL-33 
to sST2, the signaling via ST2L is inhibited [57]. Elevated serum sST2 has been detected 
in patients with asthma [58], acute heart failure [59], ulcerative colitis [59] and sepsis 
[60]. This elevated level of serum sST2 showed a positive correlation with disease 
severity and mortality in patients with severe sepsis. When soluble ST2-Fc was 
administered to mice, it effectively attenuated inflammation and lethality after intestinal 
ischemia and reperfusion injury [61].  It is suggested ST2 signaling is involved in 
regulating the inflammatory response. 
IL-33 may act in an autocrine or paracrine manner. IL-33 binds to its membrane 
receptor ST2L which forms a complex with IL-1 receptor accessory protein (IL-1RAcP) 
[62]. This leads to sequestering MyD88 and MAL. This results in activation of TNF 
receptor-associated factor 6 (TRAF6) mediated by Interleuin-1 receptor-associated kinase 
(IRAK), with subsequent activation of mitogen-activated protein kinase (MAPK) and 
inhibition of IκB kinase (IKK) and NF-κB [63, 64]. General events downstream of IL-
33/ST2 signaling may include activation of NF-κB [64], activator protein-1 (AP-1) [65] 
and, phosphorylation of p38 MAPK, extracellular signal-regulated kinase (ERK) 1/2, and 
c-Jun N-terminal kinases (JNK) [50]. 
Cardiomyocytes, as a response to biomechanical strain, will become fibrotic by 
laying down more collagen. Exposure to IL-33 has been shown to attenuate this response 
by reducing fibrosis [56] suggesting that IL-33 could be a potential mediator of cardiac 
collagen organization. IL-33 has been observed to participate in various inflammatory 
conditions as well such as in inflammatory bowel disease, ulcerative colitis [66].  
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Section 1.7: Matrix Metalloproteinases  
MMPs are a family of zinc-dependent endopeptidases that are able to degrade 
various components of the ECM and play a role in both physiological and pathological 
processes such as uterine involution, embryogenesis, metastasis and arthritis [67-70].  
The first MMP to be purified by Gross and Lapiere in 1962, came from tadpole tails. It 
was initially characterized by its ability to degrade collagen. Hence it was named 
collagenase-1 (now referred to as MMP-1) [71]. Since its discovery, over 20 MMP 
species have been identified. It was quickly observed that their substrates ranged 
anywhere from structural proteins to non-ECM substrates.  Because of their wide range 
of substrates, MMP can actively participate in many cellular function including cell 
growth, apoptosis, cell migration, cell-cell communication and tumour progression [72].  
Of particular interest, MMPs have been implicated in various cardiac pathologies 
including heart failure, myocardial remodeling and dilated cardiomyopathy [73-75]. 
MMPs are initially secreted as a latent zymogen or pro-MMP and tightly 
controlled at the level of transcription, translation and activation by proteolytic cleavage 
[76].  In pro-MMPs, the cysteine residue in the propeptide domain creates a bond with 
the Zn
2+
 site in the catalytic domain, inactivating the proenzyme [77]. When this bond is 
replaced by a water molecule in a step called “cysteine switch”, the MMP’s catalytic 
domain is released and which produces an intermediate active enzyme [77].  To fully 
activate the MMP, the pro-domain needs to be cleaved by proteases or autolytic cleavage 
[77].  Their activity is also regulated by different inhibitors, most important of which is 
tissue inhibitors of metalloproteinases (TIMPs) [78]. MMP-9 can degrade wide range of 
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substrates including gelatin (a denatured fibrillar collagen), collagen type IV, fibronectin 
and laminin [74]. 
 
Section 1.7.1: MMP-9 and Sepsis 
MMP-2 and MMP-9 are capable of degrading different components of the ECM 
and both have been previously demonstrated to be highly expressed in the heart [79]. In 
addition, it has been shown that cardiomyocytes are capable of expressing these MMPs 
[75]. LPS has been shown to induce transcription of MMP-9 in cell culture experiments 
[80, 81].  Rats injected with LPS as a model of sepsis, have increased MMP-9 activity in 
heart perfusates, whereas MMP-2 activity was decreased with LPS. Administering MMP 
inhibitor reduced MMP-9 activity and significantly improved cardiac function [82]. 
Metalloproteinase inhibition was also shown to improve survival after cecal ligation and 
puncture (CLP) in rats [83]. In a clinical study, higher plasma MMP-9 [84] and ST2 
levels [60] in septic patients directly correlated with mortality. 
A novel observation was made in the rat sepsis model which had decreased 
collagen content in the myocardium [13]. However, the detailed relationship between 
collagen remodeling and sepsis is not fully understood. It is speculated that MMPs play 
an important role in septic myocardial collagen remodeling. 
Elevated MMP expression was also associated with septic patients [85]. TNF-α, 
an important cytokine mediating septic pathophysiology and classified as a myocardial 
depressant substance, has also been identified to induce MMP gene transcription. [86].  
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Section 1.8: Animal Sepsis Models 
There are several different animal models of sepsis that researchers have used. 
Each have their own advantages and disadvantages in representing clinical sepsis. The 
simplest is the LPS model. This model of sepsis assumes that sepsis is not caused by the 
intact pathogen but relies on host’s response to it.  A set dose of LPS is administered 
intravenously or into the abdominal cavity of the animal, which causes sepsis-like 
symptoms such as hematological changes [88]  and increased release of proinflammatory 
cytokines [89].  Cytokines, TNF-α and IL-1 mediate LPS-induced response in the animal. 
With this promising result clinical trials attempted to reproduce this by treating septic 
patients with TNF-α antibodies, but it failed [90]. The LPS infusion model and clinical 
sepsis have major differences, especially characteristics of cytokine release. In human 
sepsis, cytokine levels were lower and peaked later than those of LPS models [88, 91]. 
Also blocking LPS with antibodies in septic patients did not alter their outcome (33). 
Overall, although the model allows accurate doses of LPS to be administered and easily 
stored, it may not effectively simulate human sepsis. 
Another sepsis model commonly used is cecal ligation and puncture (CLP). Like 
the name implies the animal is ligated just below the ileocecal valve and the cecum is 
punctured with a needle. This provides a polymicrobial infection focus as the contents of 
cecum slowly leaks out into the peritoneal cavity. The animals have similar 
characteristics of sepsis with high mortality [92]. Like in human sepsis, high levels of IL-
6 in CLP animals correlated with decreased survival [93]. Although the CLP model 
shows clinical relevance, it is difficult to achieve consistent data. Several steps in the 
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procedure can alter the outcome including the length of the cecum ligated and individual 
composition of bacteria. 
In our study we chose to use the FIP model. FIP involves making a fecal slurry 
with feces taken from a donor animal and injecting it into the peritoneal cavity of the 
experimental animal. Similar to the CLP model, feces inoculation provides a mixture of 
all different bacteria present in the feces, thus creating a polymicrobial infection. 
Although it does not reproduce a continual release of infectious focus like CLP, it is 
advantageous over CLP in that the investigator is able to better control how much feces is 
injected into the peritoneal cavity. Also since all the animals in the experimental group 
are getting treated with the fecal slurry prepared from a single donor, the amount of 
bacterium in the feces can be controlled. 
 
Section 1.9: Purpose of Study 
Etiologies of sepsis-induced cardiac dysfunction remain unclear. Previous studies 
have reported that septic hearts go through various structural changes. Studies report 
involvement of both MMP-9 and IL-33 in various cardiomyopathies by altering the 
myocardial structure. IL-33 has been implicated in regulating collagen turnover where it 
reduced fibrosis in pressure overloaded heart [87]. Increased MMP-9 activity has been 
measured in plasma of sepsis patients [85] and MMP-9 inhibitor reduced the mortality 
rate of septic rats [83]. It is speculated that changes in myocardial collagen during sepsis 
are mediated by IL-33 via regulation of myocardial MMP-9. Purpose of this study was to 
deduce pathological mechanisms of sepsis which lead to cardiac dysfunction. 
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Section 1.10: Hypothesis 
IL-33 will contribute to myocardial dysfunction observed in a mouse sepsis model which 
may be carried out partly through regulation of MMP-9 expression in cardiomyocytes 
(Figure 1.1). 
 
Section 1.11 Objectives of Thesis 
1. Generate a mouse sepsis model. Inject fecal slurry into mice peritoneum (FIP 
model) to induce systemic inflammation. Compare hematological parameters and 
lactate levels to clinical observations.  
2. Assess heart tissues for changes in cardiac collagen content. Determine if FIP 
treated mice has differential collagen staining compared to control. 
3. Evaluate myocardial expression of IL-33 and MMP-9 and how they correlate with 
cardiac function in FIP mice. 
4. Investigate whether IL-33 inhibition affects myocardial function and MMP-9 
expression in FIP mice. 
5. Use an in vitro model to study how cardiomyocytes respond to LPS. 
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Figure 1.1 Schematic diagram of proposed hypothesis 
IL-33 will contribute to myocardial dysfunction observed in mice sepsis model which 
may be carried out through regulation of MMP-9 expression in cardiomyocytes. 
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CHAPTER 2: MATERIALS AND METHODS 
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Section 2.1: Animals 
C57BL/6 mice were obtained from Charles River Laboratories Canada (St. Constant, 
Quebec, Canada). The mice were housed in Victoria Research Labs Vivarium Service 
with a 12-hour light/dark cycle with access to rodent chow and water ad libitum. The 
mice were used for in vivo experiments as well as a source for neonatal cardiomyocytes 
for in vitro experiments. The experimental protocols were approved by the University of 
Western Ontario Animal Care and Use Committee (protocol no. 2006-111-11). 
 
Section 2.2: Feces-induced peritonitis 
10 week-old mice were divided into three groups of intraperitoneal injections: Sham; FIP 
or FIP+ST2. The sham group received normal saline, the FIP group received fecal slurry 
(32 mg/ 100 g body weight), and the FIP+ST2 group received fecal slurry (32 mg/ 100 g) 
and sST2 (0.2 mg/ 100 g). The fecal slurry was prepared from collecting the bowel 
contents of a mouse from same litter. It was suspended in normal saline so that equal 
volume of 800 µl was injected per mice. 
 
Section 2.3: Measurement of Cardiac Function 
There are numerous ways to assess cardiovascular parameters. There are non-invasive 
techniques such as echocardiography and magnetic resonance imaging (MRI). 
Echocardiography is an inexpensive method to observe structures in vivo using sound 
waves. The CO and shortening fraction of the heart can be estimated but it is limited by 
subjective interpretation. MRI provides a better estimation as it provides higher 
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resolution. There are also in vitro techniques that utilize a whole heart preparation or 
isolated myocytes. Isolated heart system allows the investigator to examine the effect of 
specific compounds without any contribution from other organs. Similarly the 
contractility for cell systems can also be measured and potential cellular mechanisms can 
be deduced. However in vitro systems are limited in their interpretation with regards to 
how it translates to clinical situations. In our study we chose to do invasive hemodynamic 
monitoring via arterial catheterization. This tool is used in clinical settings to directly 
measure patient’s CO, stroke volume and even venous oxygen saturations. It measures 
parameters such as intracardiac pressures, believed to reflect the current myocardial 
condition.  
In our study, mice were anesthetized with ketamine (150 mg/kg) and xylazine (5 mg/kg) 
subcutaneous 48 hours after fecal inoculation. A Millar tip transducer catheter (Model 
SPR-893, 1.4 Fr.) was inserted into the left ventricle via the right carotid artery. Various 
cardiac parameters were measured using PowerLab system (AD Instruments) connected 
to Millar catheter, including left ventricular (LV) pressure-volume (PV) loops which 
were generated by occluding the inferior vena cava. The LV end-systolic pressure-
volume relationship (ESPVR) was used, along with other parameters such as stroke work, 
as a measurement of myocardial contractile function. Plotting pressure versus volume has 
been used not only in cardiology but also in respiratory systems to measure the amount 
and efficiency of the work done. When LV pressure and volume is plotted in real time, 
one closed loop is generated per single cardiac cycle. From this loop, various parameters 
such as stroke volume, CO, ejection fraction can be calculated. ESPVR provides a more 
accurate measurement of cardiac function because it does not depend on ventricular load. 
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For example, dP/dt max represent the maximum rate of pressure change in the left 
ventricle and is used as an index of ventricular performance. Though it does provide 
valuable information it is dependent on preload, after load, heart rate and myocardial 
hypertrophy. ESPVR depicts maximum pressure that is generated at any LV volume. 
During animal surgery the inferior vena cava is occluded reducing the volume and slowly 
allowed to flow back into left ventricle. While this is happening, a series of PV loops are 
generated and a line is drawn connecting the point where systole ends on every loop. This 
generates a straight line and the slope of this line is used as an index of myocardial 
contractility. Steeper ESPVR represents stronger contractility. 
 
Section 2.4: Hematological analysis 
Approximately 1 mL of whole blood (treated with heparin) was drawn via cardiac 
puncture of the left ventricle from animals at certain time points after treatment. Whole 
blood samples were analyzed with a UniCel DxH 800 Coulter Cellular Analysis System 
(Beckman Coulter, Fullerton, CA) for complete blood counts. Blood smears were made 
and stained with Wright-Giemsa for white blood cell differentials which were analyzed 
by a specialized technologist. The technologist was not told which samples belonged to 
which group. Wright-Giemsa stain is a modified combination of Wright’s and Giemsa’s 
stain and is commonly used to stain peripheral blood and bone marrow smears. The 
important components of this dye include methylene blue, azure B and eosin Y. The 
acidic DNA of nucleus will be stained shades ranging from blue to purple by the basic 
methylene blue and azure B dyes while acidic eosin Y stains the basic cytoplasm varying 
degrees of orange and pink [94]. This allows for accurate interpretation of cell 
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morphology in the blood smear. The other types of stains, Romanowsky, Wright’s and 
Giemsa, mainly vary in proportion of agents. The Wright-Giemsa stain was chosen 
because it is a widely used stain that has been optimized to produce accurate histological 
staining for identification of different blood cell types. 
 
Section 2.5 Measurement of circulating factors 
Full-strength plasma samples were used for LPS (ToxinSensor™ Chromogenic Limulus 
Amebocyte Lysate Endotoxin Assay Kit, GenScript, NJ), IL-33 enzyme-linked 
immunosorbent assay (ELISA) (Quantikine Mouse IL-33 Immunoassay, R&D Systems, 
MN) and lactate measurement (YSI 2300 STAT Plus
™
 Glucose & Lactate Analyzer, YSI 
Life Science, OH). 
The Limulus amebocyte lysate (LAL) assay is a popular quantitative method used to 
detect endotoxin in biological samples. It provides several advantages such as sensitivity 
and specificity. The assay depends on the clotting of a protein from amebocytes of 
horseshoe crab (Limulus polyphemus) as it reacts to endotoxin. The lysate from 
amebocytes were very sensitive to endotoxin [95] and thus utilized as a diagnostic tool in 
the laboratory. For a long time, the LAL assay was the only practical method to measure 
endotoxin as it was difficult developing antibodies for such heterogeneous substance. It is 
only recently that companies have developed an ELISA kit for detecting LPS.  
The commercially-available ELISA kit was purchased for detection of plasma IL-33. 
ELISA is used in the lab measure an antigen or antibody in a sample by using antibodies 
or antigen coupled to an easily-assayed enzyme. Accurate results can be obtained with 
ELISA because it combines specificity of antibodies and sensitivity of enzymes. It is 
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much faster and cheaper than a western blot. Also it is advantageous if you have many 
samples to run at once. 
 
Section 2.6: Picrosirius staining of the heart tissue 
The picrosirius red stain is a strong anionic dye which was first described in 1979 as a 
novel method to detect collagen by its ability to bind basic amino acids of collagen fibers 
[96, 97]. Picrosirius red staining is an excellent way to detect and analyze collagen in 
tissue sections without the concerns of the stain fading over time. Specifically, picrosirius 
red is able to consistently stain collagen fibers including thin collagen fibers that other 
traditional stains (e.g. van Gieson, trichrome) fail to detect which can lead to 
underestimation of total collagen [98, 99].  
For this study, the heart was excised from the mouse and was fixed in 10% formalin 
before being embedded in paraffin. The tissue was cut in sections of 5 µm and transferred 
to glass slides. Slides were de-paraffinized in two changes of xylene for 10 minutes and 
hydrated following a series of washes: two changes of 100% ethanol for 10 minutes, two 
changes of 95% ethanol for 5 minutes, 80% ethanol for 2 minutes and 70% ethanol for 2 
minutes. The slides were washed in water for 3 minutes before staining with picrosirius 
red (0.8%) for 1 hour at room temperature. The stained slides were dehydrated in two 
changes of 100% ethanol and cleared in xylene. They were then mounted with a glass 
cover slip in Eukitt quick-hardening mounting medium (Sigma Aldrich, St. Louis, MO). 
When viewed under brightfield microscope (20X objective lens) the collagen appeared 
red on a yellow background. The pictures taken of the slide (5 fields per slide) were 
analyzed using Sigma-Scan Pro software. The percentage of collagen staining was 
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calculated as a percentage of the whole tissue. The staining solution consisted of 0.5 g 
Sirius red (Sigma-Aldrich, Cat#365548) and 500 mL picric acid solution (Sigma-Aldrich, 
Cat#P6744-1GA). 
 
Section 2.7: Primary neonatal mouse cardiomyocyte culture 
Neonatal mice (C57BL/6) were anaesthetized and the chest was cut open with sterilized 
pair of scissors. Hearts were excised and immediately transferred to ice-cold D-Hanks 
solution in a 50 mL tube. The hearts were washed and minced into ~1mm
3
 small pieces. 
The heart pieces were resuspended into 2 mL of pre-warmed 37 °C Liberase working 
digestion solution (Liberase TM Research Grade, Roche, IN). Tissue pieces were 
dispersed and cells were released with a transfer pipette until the supernatant became 
cloudy. The supernatant was collected in a 15mL tube. This digestion procedure was 
repeated two more times with remaining heart pieces and the supernatant collected. The 
collected supernatant was centrifuged at 200 g for 5 minutes. The supernatant was 
discarded and the pellet was resuspended in medium 199 (M199) containing 10% fetal 
bovine serum (FBS). The resuspended cells were preplated in a petri dish for 1 hour for 
fibroblast adhering to enrich for cardiomyocytes. The cardiomyocyte-rich supernatant 
was collected and seeded into tissue culture plates (Costar) pre-coated with 0.1% gelatin. 
After 48 hours, the conditions of cardiomyocytes were checked under the microscope to 
see that they formed a confluent monolayer and were beating spontaneously infrequently. 
The isolated cardiomyocyte culture was subjected to LPS administration (LPS-EK, 
InvivoGen). Cardiomyocytes were treated with LPS (1 µg/mL) for 4, 8 or 24 hours.  
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Section 2.8: SDS-PAGE and western blot 
Western blot is a popular analytical technique used to quantify specific proteins by using 
antibodies. The denatured protein sample from source of interest is separated by size with 
polyacrylamide gel electrophoresis (PAGE) and transferred to a carrier-membrane (e.g. 
polyvinylidene difluoride, PVDF or nitrocellulose) which is incubated in a specific 
antibody to your protein of interest. A secondary antibody will bear the reporter which 
will luminesce when exposed to its substrate. This chemiluminescent signal is then 
detected by a camera or X-ray film and the quantity of protein is determined by optical 
density. Western blot is useful in detecting several proteins from a single sample. Since 
the carrier-membrane contains all proteins from your sample, different proteins can be 
detected by using different antibodies. In our study, cardiomyocytes were washed with 
ice-cold phosphate buffered saline (PBS) three times and sodium dodecyl sulfate (SDS) 
loading buffer was added. After sonication using 4710 Series Ultrasonic Homogenizer 
(Cole Parmer Instrument Co.) and heating on VWR Digital Heatblock, protein 
quantification was done using the Bio-Rad protein assay. Equal quantity of each protein 
samples were loaded into SDS-PAGE gel (12%) for electrophoresis. Then the protein 
was transferred to PVDF membranes. Nonspecific binding to the blot was blocked with 
3% milk blocking solution made from Blotting Grade Blocker Non-Fat Dry Milk (Bio-
Rad) then incubated with a primary antibody against IL-33 (R&D; 1:1000), ST2 (Abcam 
Inc; 1:500) or MMP-9 (Cell Signaling; 1:1000). An internal control antibody anti-
housekeeping protein, tubulin (Abcam Inc; 1:500), was used as protein loading control.   
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Section 2.9: Measurement of MMP-9 activity 
Expression of MMP-9 was examined by gelatin zymography. This technique utilizes the 
gelatinolytic activity of proteases to quantitatively analyze the concentration of protein. A 
gel was made just as regular SDS-PAGE gel except it was co-polymerized with gelatin. 
After loaded protein sample was separated according to size, the SDS is washed away 
from gel with Triton-X, which allows MMPs to renature. Any MMPs present is able to 
degrade gelatin while incubating in calcium-containing developing buffer. Since there are 
two species of MMPs that degrade gelatin (MMP-2, 72kDa and MMP-9, 92 kDa) the 
predicted molecular weight of the MMP allows identification of which gelatin clearing is 
attributed to which MMP.  
Gelatin zymography is a qualitative method to detect gelatinolytic activity, and from that, 
the expression level of MMP expressed is analyzed [100]. Zymography offers many 
advantages over other methods such as ELISA. It is relatively inexpensive as it does not 
require antibodies and one gel can detect multiple proteases which share the same 
substrate. Gelatin zymography is commonly used to study gelatinases MMP-2 (72 kDa) 
and MMP-9 (92 kDa) which can be differentiated on the gel according to size. 
Gelatin (Gelatin from porcine skin, Type A, Sigma) was copolymerized to 10% 
polyacrylamide gels at 0.1% concentration. The cardiomyocyte conditioned media was 
concentrated using a centrifugal filter before analyzing with gelatin zymography. Non-
heated concentrated media, cell lysate or tissue homogenate samples plus 5x loading dye 
were loaded along with a positive control, recombinant MMP-9 (R&D Systems, 
Minneapolis, MN). After 2 hours of eletrophoresis, the gels were washed in 2.5% Triton 
X-100 (Sigma) for 30 minutes with gentle agitation at room temperature to remove SDS. 
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After, the gels were incubated in zymogram developing buffer (50 mM Tris-HCl, 0.2M 
NaCl, 5 mM CaCl2, and 0.02% Brij 35) for 30 minutes at room temperature with gentle 
agitation. The buffer was replaced with fresh developing buffer and gels were incubated 
at 37 ºC overnight. After the incubation the gels were stained with Coomassie Blue R-250 
(Sigma) in a mixture of 5% methanol:10% acetic acid until the gels were stained 
uniformly dark blue. The gels were destained in aqueous 10% methanol: 5% acetic acid. 
Areas of gelatinolytic activity were detected as clear bands against the dark blue 
background. Zymograms were scanned and band intensities were quantified. 
 
Section 2.10: Statistical analysis 
All values are presented as mean ± standard error of the mean (SEM). Statistical analysis 
was performed using Student’s t-test or analysis of variance (ANOVA) with a Tukey’s 
post-hoc test to compare multiple groups. Student’s t-test was used to compare the means 
of 2 groups and ANOVA was used to compare the means of more than 2 groups. 
Differences between groups were considered significant if the P < 0.05. 
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CHAPTER 3: RESULTS 
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Section 3.1: Establishing murine sepsis model 
 
To characterize the established mouse sepsis model, white blood cell differential 
and platelet count was completed for FIP mice at different time points (Table 3.1) Also 
plasma lactate was measured using STAT Plus
™
 Glucose & Lactate Analyzer (Table 3.2).  
A similar pattern was observed in FIP mice – decreased platelet count, increased 
neutrophils and decreased lymphocyte differentials – as seen in other animal sepsis 
models [101]. There was no difference in plasma lactate concentration, in contrast to 
observations made in past studies [102]. 
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Table 3.1. White blood cell differential and platelet count 
 
 Neutrophils (%) Lymphocytes (%) Platelets (10
3
/µL) 
Sham 16.00±1.92 81.80±1.7 1046.1±61.74 
FIP 6h 60.80±7.02*** 36.80±6.39*** 767.64±30.26** 
FIP 24h 45.67±2.73* 48.67±0.88** 721.4±71.63** 
FIP 48h 57.67±8.01** 37.00±7.81*** 868.83±24.35 
    
After onset of sepsis % lymphocytes and platelet count are decreased, while % 
neutrophils is increased. FIP was induced by injecting a fecal slurry into the mouse 
peritoneal cavity and a blood sample was collected at various time points. Values are 
mean ± SEM, n=3-5/group, *p<0.05, **p<0.01, ***p<0.001 vs. sham. 
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Table 3.2. Plasma concentration of lactate 
 
Plasma Lactate (mmol/L) 
Sham 1.022 ± 0.297 
FIP 6h 1.538 ± 0.358 
FIP 24h 0.940 ± 0.147 
FIP 48h 1.071 ± 0.176 
  
There was no difference in lactate measured in FIP mice compared to sham. FIP was 
induced by injecting a fecal slurry into the mouse peritoneal cavity and a blood sample 
was collected at various time points. Values are mean ± SEM, n=4/group. There were no 
significant differences between time points. 
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Section 3.2: ST2 prevents cardiac dysfunction observed in FIP mice 
 
In order to compare the hemodynamic patterns of different treatment groups: 
sham, FIP and FIP + ST2-treatment, left ventricle function was measured with a Millar 
catheter-tip pressure transducer 48 hours after individual treatment. Mice with FIP had 
cardiac dysfunction compared to saline controls (Table 3.3). The dysfunction induced by 
FIP was prevented upon sST2 injection, a decoy receptor of IL-33 (Table 3.3). The left 
ventricular end-systolic pressure (LVESP) (93.4 ± 2.1 vs. sham 109.2 ± 0.8), velocity 
of contraction (dP/dt max; 5243 ± 429 vs. sham 7291 ± 279), stroke work (759.5 ± 
107.4 vs. sham 1208.8 ± 110.1) and end systolic pressure-volume relationship (ESPVR) 
(3.6 ± 0.1 vs. sham 4.7 ± 0.3) all were significantly impaired in FIP mice compared to 
sham control mice (Figure 3.1). sST2 treatment had statistically significant prevention of 
dysfunctions (LVESP, 106.1 ± 5.5 vs. FIP 93.4 ± 2.1; dP/dt max, 7105.5 ± 118.8 vs. 
FIP 5243 ± 429; stroke work, 1176 ± 162.8 vs. FIP 759.5 ± 107.4; ESPVR, 4.6 ± 0.2 
vs. FIP 3.6 ± 0.1). It appears that sST2 has a protective role against the deteriorative 
effects FIP has on mouse cardiac contractility.  
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Table 3.3. In vivo hemodynamic measurements  
Parameters Sham (n=5) FIP (n=6) FIP+ST2 (n=4) 
HR (b.p.m) 304 ± 18 305 ± 14 308 ± 18 
MAP (mmHg) 39.4 ± 0.4 35.1 ± 0.9 39.2 ± 2.1 
LVESP (mmHg) 109.2 ± 0.8 93.4 ± 2.1* 106.1 ± 5.5# 
LVEDP (mmHg) 15.4 ± 1.9 14.5 ± 3.6 10.5 ± 2.2 
SV (µL) 15.4 ± 0.9 11.9 ± 1.6 14.4 ± 1.1 
EF (%) 20.5 ± 1.0 18.0 ± 1.7 18.5 ± 2.0 
CO (µL/min) 4722.7 ± 521.1 3595.0 ± 425.4 4401.4 ± 296.5 
SW (mmHg*µL) 1208.8 ± 110.1 759.5 ± 107.4* 1176 ± 162.8# 
dP/dt max (mmHg/s) 7291 ± 279 5243 ± 429* 7105.5 ± 118.8# 
dP/dt min (mmHg/s) -7024 ± 698 -5842 ± 564 -5793 ± 720 
ESPVR (mmHg/µL) 4.7 ± 0.3 3.6 ± 0.1* 4.6 ± 0.2# 
    
HR, heart rate; MAP, mean arterial pressure; LVESP, left ventricular end systolic 
pressure; LVEDP, left ventricular end diastolic pressure; SV, stroke volume; EF, ejection 
fraction; CO, cardiac output; SW, stroke work; dP/dt max, maximal rate of pressure rise; 
dP/dt min, maximal rate of pressure decline; ESPVR, end systolic pressure-volume 
relationship. Data are mean ± SEM. *P<0.05 vs. sham, #P<0.05 vs. FIP.  
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Figure 3.1. Soluble ST2 prevents cardiac dysfunction caused by feces-induced 
peritonitis. 
 
Cardiac function of mice subjected to FIP in vivo. A) Representative left ventricular 
pressure-volume loops. B) Quantitative analysis of ESPVR. C) Analysis of dP/dt max 
and stroke work. FIP treatment decreased various cardiac parameters while sST2 
treatment prevented these effects. Data are mean ± SEM, n=3-6/group, *p<0.05 vs. sham, 
#p<0.05 vs. FIP.  
 
 
Sham                                         FIP                                     FIP+ST2 
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Section 3.3: Collagen staining 
 
Hearts were collected from FIP/sham mice 48 hours after treatment and stained 
using picrosirius red solution. There was no difference in cardiac collagen staining 
between sham control and FIP mice (Figure 3.2). 
 
A 
 
 
 
 
B 
 
 
 
 
 
 
Figure 3.2. Collagen staining of FIP myocardium 
A) Representative micro-pictures. Collagen stains red against a yellow tissue background. 
B) Quantification of collagen content. The numbers are reported as ratio between 
collagen staining and area of tissue. There was no difference in collagen content between 
sham and FIP mice. Data are mean ± SEM, n=3/group.  
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Section 3.4: Expression of IL-33 and MMP-9 in FIP mice 
 
Hearts were harvested from FIP/sham mice after 24 or 48 hours. Cardiac tissue 
protein expression of IL-33 and MMP-9 were detected using western blot. A significant 
increase in IL-33 expression was observed in the myocardium from FIP mice that peaked 
at 24 hours after fecal injection. It returned to basal levels after 48 hours post-FIP (Figure 
3.3A). The expression of MMP-9 showed a different time-course than that of IL-33. 
MMP-9 expression also increased with time however it was seen to be continually 
increasing well over the 24 h time-point, at which expression of IL-33 peaked. MMP-9 
expression in cardiac tissue was seen to be significantly increased 48 hours after fecal 
injection (Figure 3.3B).  
Mouse plasma was also collected to measure circulating IL-33 levels using 
ELISA. The circulating IL-33 was not detected within the range of sensitivity offered by 
the ELISA kit (data not shown).  
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Figure 3.3: FIP leads to increased expression of myocardial IL-33 and MMP-9. 
Densitometric analysis of A) IL-33 and B) MMP-9. Representative western blots are 
shown above. IL-33 and MMP-9 levels increased in FIP mice myocardium compared to 
sham controls. IL-33 levels peaked at 24 hours while MMP-9 levels were slower to rise. 
Data are mean ± SEM, n=3-4/group, *p<0.05 vs. sham, #p<0.05 vs. 24h.  
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Section 3.5: Myocardial MMP-9 in FIP mice using gelatin zymography 
 
Level of MMP-9 in heart tissue was also measured by utilizing the protein’s 
ability to degrade gelatin. There was significant gelatin clearing at 92kDa region in 
sample lanes loaded with heart lysate from FIP mice 48 hours after treatment (Figure 3.4). 
The increased MMP-9 activity indicates higher protein concentration in those heart 
samples.  
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Figure 3.4: FIP leads to increased expression of myocardial MMP-9 
Representative zymogram reveals presence of MMP-9 activity in heart tissue samples 
from FIP mice, 48 hours-post inoculation. Densitometric analysis of specific 92 kDa 
gelatinolytic activity is shown below. Data are mean ± SEM, n=3/group, *p<0.05 vs. 
sham.  
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Section 3.6: Soluble ST2 prevents augmentation of MMP-9 expression in FIP mice 
myocardium 
 
To elucidate the relationship between IL-33 pathway and regulation of MMP-9 in 
mice myocardium, FIP mice were treated with sST2, a decoy receptor of IL-33, 8 hours 
post fecal injection. 48 hours after FIP initiation the heart was excised out and gelatin 
zymography was performed with tissue lysate. As observed previously, FIP treated mice 
have increased activity of MMP-9 in its myocardium lysate. In FIP mice treated with 
sST2 the induction of MMP-9 in myocardium lysate is inhibited (Figure 3.5).  
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Figure 3.5. ST2 prevents MMP-9 induction in FIP mice heart 
Representative zymogram reveals presence of MMP-9 activity in heart tissue samples 
prepared 48 hours after treatment. The increased gelatinolytic activity in FIP mice heart 
was prevented by sST2 treatment. Densitometric analysis of specific 92 kDa gelatinolytic 
activity is shown below. Data are mean ± SEM, n=3/group, *p<0.05 vs. sham, #p<0.05 
vs FIP.  
 
 
92 kDa 
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Section 3.7: Endotoxin levels, comparison between in vivo and in vitro system 
 
In order to determine if fecal inoculation released significant amount of endotoxin 
into the circulation, the plasma samples were collected at various time points after the 
initiation of peritonitis. Endotoxin in the circulation was significantly increased 1 hour 
after fecal inoculation and rapidly cleared out of the system (Figure 3.6A). The LPS in 
regular growth cell culture media and LPS-treatment cell culture media were also 
quantified (Figure 3.6B). All samples were analyzed with commercially available 
Chromogenic Limulus Amoebocyte Lysate Endotoxin Assay kit from GenScript 
(ToxinSensor™). This kit measures endotoxin based on its biological activity. It was 
found that 1 µg of LPS does not translate to full biological activity; only 643.2  1.3 pg 
of active LPS was measured (Figure 3.6B). 
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Figure 3.6: Measurement of endotoxin in in vivo and in vitro model.  
A commercial endotoxin detection kit was used to measure A) endotoxin present in full-
strength plasma from FIP mice and B) cell culture treatment media with LPS (1 µg/mL in 
M199).  FIP treatment increased circulating LPS which was significant after 1 hour. It 
was seen with cell culture treatment media that not all of LPS present exhibit endotoxic 
activity. Data are mean ± SEM, n=6/group, *p<0.05 vs. control. 
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Section 3.8: LPS induces IL-33 expression in cultured cardiomyocytes 
 
To determine the expression profile of IL-33 induced by LPS, primary 
cardiomyocyte culture isolated from neonatal mice was treated with LPS (1 µg/ml) in 
M199 supplemented with FBS.  After 4, 8, or 24 hours the cell lysate was collected to be 
analyzed by western blot. IL-33 expression was significantly increased 4 hours after LPS 
administration and peaked at 8 hours. LPS-induced IL-33 expression started to decline at 
24 hours back to basal levels (Figure 3.7).  
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Figure 3.7: LPS treatment increases IL-33 expression in cardiomyocytes. 
Representative western blots are shown above and densitometric analysis below. LPS 
treatment increased IL-33 expression in cardiomyocytes compared to control, which 
peaked around 8 hours. Data are mean ± SEM, n=3/group, *p<0.05 vs. control 
(M199+10% FBS). 
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Section 3.9: Cardiomyocytes secrete MMP-9 in response to LPS 
 
To determine if LPS can induce release of MMP-9, the cardiomyocytes were 
treated with LPS (1µg/ml) in M199 without serum. MMP-9 expression in the conditioned 
media was significantly increased 8 hours after LPS treatment (Figure 3.8). There was no 
detectable level of intracellular MMP-9 (data not shown).  
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Figure 3.8: LPS treatment increases MMP-9 release from cardiomyocytes. 
Representative zymogram of MMP-9 in cardiomyocyte culture media is shown above 
and densitometric analysis below. The 92 kDa gelatinolytic activity in the media is 
significantly increased 8 hours after LPS treatment. Data are mean ± SEM, n=3/group, 
*p<0.05 vs. M199. 
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Section 3.10: Soluble ST2 inhibits induction of MMP-9 in cardiomyocytes 
 
Similar to what was done in vivo where FIP mice were treated with sST2, the 
cardiomyocytes were treated with LPS (1 µg/mL) or LPS+ST2 (100 µg/mL) or M199 
alone to look at the IL-33/ST2 and MMP-9 relationship. As we observed before, LPS 
induced cardiomyocytes released significant amount of MMP-9 into the cell culture 
media. This increase was inhibited in cell culture treated with LPS and sST2 (Figure 3.9).  
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Figure 3.9: Soluble ST2 inhibits LPS-induced MMP-9 release from cardiomyocytes. 
Representative zymogram of MMP-9 activity in cardiomyocyte culture media is shown 
above and densitometric analysis below. LPS-induced 92 kDa gelatinolytic activity is 
prevented by sST2 treatment. Data are mean ± SEM, n=3/group, *p<0.05 vs. M199, 
#p<0.05 vs LPS. 
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CHAPTER 4: DISCUSSION 
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Cardiac dysfunction is a major contributing factor to increased morbidity and 
mortality in septic patients. However, the exact cellular mechanisms underlying the 
maladaptive changes are not yet fully elucidated. This study demonstrates, for the first 
time, that IL-33 may contribute to the myocardial depression observed in the mouse 
sepsis model. Feces inoculation in the mice peritoneal cavity successfully reproduced the 
hematological patterns commonly observed in clinical sepsis. Using this model, the 
results showed increased expression of IL-33 and MMP-9 in mouse myocardium which 
was reproduced in cell culture studies where cardiomyocytes were treated with LPS. Also, 
inhibition of IL-33 using a decoy receptor, sST2, prevented decreases in cardiac function 
observed in FIP treated mice. This was reproduced in cell culture studies where LPS-
induced MMP-9 expression in cardiomyocytes was inhibited by sST2 treatment. 
Previous studies have reproduced cardiac dysfunction in animal models of sepsis 
[103] and endotoxemia [104].  To establish a comparable sepsis animal model, 
hemodynamic and hematological characteristics were compared and observed to be 
similar to previous animal models [101] and clinical studies. However the plasma lactate 
levels were opposite to what is most commonly observed [105]. This may be attributed to 
a variety of things. Serum lactate level is a balance of lactate production and utilization. 
Hence, it will not only depend on processes that increase lactate production, but also on 
how much is used. Hyperlactatemia is prevalent in many septic patients, and lactate 
levels serve as a good diagnostic index [102]. The common understanding of 
hyperlactatemia in shock is that it’s a secondary response to tissue hypoxia brought upon 
by tissue hypoperfusion. This indeed is the case for some septic situations but certainly 
not all. Previous studies have reported hypoxia-induced hyperlactatemia in septic patients 
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with low cardiac output, where high lactate levels predominantly reflect poor oxygen 
delivery [106, 107]. There are also cases where hyperlactatemia in septic shock cannot be 
solely attributed to anaerobic metabolism. If lactate production came from hypoperfused 
organs, we would expect to see decreased ATP levels. This was not the case when they 
measured ATP levels from muscle, which turned out to be normal [108]. Hence, it 
appears that elevated lactate levels observed in septic conditions may not always reflect 
tissue hypoxia and may occur from a variety of etiologies. Though we did not observe a 
difference in lactate levels in our model of sepsis, it cannot be concluded this was solely 
due to lack of cellular hypoxia. Also, previous reports have indicated lactate improve 
heart function by acting as substrate for additional energy [109].  
Generally, there are four criteria that need to be satisfied to confirm a causal 
relationship. First, the presence and elevation of causative factor must be observed. Then, 
the response caused by factor must be attenuated by inhibiting the factor. This is then 
confirmed by reproducing the response by providing the factor. And finally, appropriate 
temporal relations are compared between the elevation of the factor and the observed 
response. In our study, three of these criteria were confirmed in in vivo and in vitro 
systems.  
This study demonstrated that the inflammatory stimulus induced by feces 
inoculation increased myocardial IL-33 and MMP-9 expression. This was demonstrated 
via western blotting and again using gelatin zymography for MMP-9. Although there 
appears to be some MMP-9 expressed at 24 hour time point as analyzed with western 
blotting (Figure 3.3B) opposed to none in gelatin zymography (Figure 3.4), this increase 
at 24 hours was not statistically significant. However, for both western blot and gelatin 
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zymography, the MMP-9 expression increased significantly at 48 hours post-feces 
inoculation. Thus, MMP-9 results from two quantitative methods were congruent, 
providing stronger evidence of MMP-9 induction. Also, comparing the time course for 
induction of IL-33 and MMP-9, IL-33 expression peaked at 24 hours, ahead of MMP-9 
induction, which peaked at 48 hours. There was no evidence of elevated IL-33 in the 
circulation when plasma samples were analyzed with ELISA. It appears that not enough 
IL-33 was produced in the myocardium and was released into the circulation and thus 
could only be measured locally (i.e. in the heart tissue).  Though we did not look at 
circulating MMP-9 in our animal sepsis model, previous studies have reported elevated 
MMP-9 in the blood of septic patients which correlated with disease severity [110].  
Our sepsis model reproduced cardiac dysfunction observed in septic patients with 
decreased cardiac function after FIP injection. These decreased hemodynamic parameters 
were prevented when IL-33 was inhibited by injecting the mice with sST2. This supports 
our hypothesis that IL-33 is involved in sepsis-induced cardiac dysfunction. In an attempt 
to better understand the process, the heart tissue from sST2-injected FIP mice were 
further analyzed. Myocardial MMP-9 was measured using gelatin zymography. We 
observed that FIP mice injected with sST2 did not have increased expression of 
myocardial MMP-9. Taking the observation that IL-33 is involved in aberrant cardiac 
function and controls expression of MMP-9, we looked at a possible target of MMP-9 
expression. 
A novel finding by Yu et al. showed there was reduction in collagen content in a 
rat model of sepsis [13]. Our animal sepsis model could not be used to analyze the impact 
of FIP on the quantity of myocardial collagen. Both the control sham and FIP groups had 
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very little collagen staining that it was difficult to accurately determine if MMP-9 altered 
the absolute collagen content, if at all, since it was hard to see any changes at a small 
scale. However, actions of MMPs are not only limited to collagen degradation. It can 
disrupt the organization of ECM matrix which alone can have aberrant effect on the 
cardiac contractility [111].  
Taking together the results that: 1) the time course of IL-33 and MMP-9 induction 
differ, with increased expression of IL-33 ahead of MMP-9 expression; 2) inhibition of 
IL-33 prevents induction of MMP-9 seems to suggest that signaling of IL-33 and MMP-9 
expression is a cause and effect relationship. The results demonstrate that the IL-33/ST2 
pathway plays a role in regulating MMP-9 expression in the myocardium and cardiac 
function of FIP treated mice.   
Although IL-33 could not be measured in the circulation in our study, it was 
significantly elevated in the heart. It is a strong indication that IL-33 mediates its effects 
at to the myocardium as many growth factors and cytokines have been known to get 
trapped in the tightly knitted ECM [112]. However, it should not be immediately 
assumed that there is a link between IL-33 and MMP-9 expression based only on time 
profile. To address this, we followed up with in vitro studies which provide a simpler 
system to study signaling mechanisms. 
We cultured primary cardiomyocytes and subjected them to LPS treatments. LPS 
is a well known myocardial depressant as seen after animals have been injected with LPS 
[113]. We have demonstrated that LPS levels are detectable in the circulation in our 
animal model and thus acceptable to use as a reasonable agent to use to treat 
cardiomyocytes. Although it was only elevated significantly for a short period of time (1 
55 
 
 
hour; Figure 3.6), it may be able to initiate the release of other mediators such as 
cytokines that relay the myocardial depressant effects on to effector proteins. LPS 
treatment has already been reported to induce expression of MMP-9 in various cellular 
systems [80, 81]. Our study aimed to identify if LPS-induced MMP-9 expression is 
regulated by IL-33 as observed in in vivo. Results showed significant induction of IL-33 
and MMP-9 expression in cardiomyocytes after LPS treatment. IL-33 was significantly 
increased 4 hours after LPS treatment and started returning back to basal level after 24 
hours. MMP-9 expression was significantly increased 8 hours after LPS treatment and 
was observed to be maintained past this time point. Similar to in vivo results, IL-33 
induction preceded MMP-9. The induction of IL-33 and MMP-9 appears to be quicker in 
vitro than in vivo and this may be due to the extra time required for gram-negative 
bacteria to shed its cell wall components into the circulation and for LPS to reach the 
myocardium. Also confirming results from sST2 injection in mice, when LPS treated 
cardiomyocytes were incubated with sST2, induction of MMP-9 was prevented.  
This study presents a novel finding where inhibition of IL-33 via sST2 treatment 
prevented LPS-induced MMP-9 expression. We demonstrated similar results where FIP-
induced MMP-9 expression in the myocardium was inhibited by sST2 inoculation. We 
have also shown a differential time induction of IL-33 and MMP-9 expression after LPS 
and FIP treatment. Taken together, the inhibition of IL-33 prevents MMP-9 induction and 
the delayed induction of MMP-9 compared to IL-33, provide support for the concept that 
IL-33 regulates the expression of MMP-9 in LPS treated cardiomyocytes.  
Potential pathways involved between LPS, IL-33 and MMP-9 need to be 
discussed. It is well documented that LPS binds to the TLR4/MD-2/CD14 complex [114] 
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and initiates subsequent MyD88-dependent signaling which will eventually activate NF-
κB via activation of MAPKs. NF-κB is a powerful inducer of innate immunity and 
triggers expression of many pro-inflammatory cytokines to mediate the inflammatory 
response [115]. This study demonstrates that LPS induces IL-33 expression in 
cardiomyocytes. It remains to be confirmed whether LPS-induced IL-33 expression is 
mediated via NF-κB. Since in our study sST2 treatment inhibited MMP-9 expression in 
cardiomyocytes, it provides a strong indication that IL-33/ST2 signaling is involved in 
LPS-induced MMP-9 expression. Cheng and colleagues also reported LPS treatment lead 
to induction of MMP-9 in cardiomyoblast cells and this was dependent upon ERK1/2 
[116]. IL-33/ST2 pathway activates several MAPK pathways and ERK1/2 is one of them 
[50]. Perhaps LPS-induced MMP-9 expression in cardiomyocytes is mediated by ERK1/2, 
activated by IL-33/ST2 signaling cascade (Figure 4.1).  
This study has demonstrated IL-33 plays a crucial role in mediating cardiac 
dysfunction in septic mice. It has been shown for the first time that myocardial 
expression of IL-33 and MMP-9 are increased after septic insult and sST2 treatment 
prevented the resulting myocardial depression. This suggests that downstream effectors 
of IL-33 have a deleterious role in altering the cardiac function after inflammatory stimuli. 
One of the effectors involved in mediating myocardial depression may be MMP-9. This 
study’s strength relies on confirming in vivo results with in vitro results. This strengthens 
the hypothesis and opens possibilities for further research to answer novel questions this 
study poses. This study has not addressed details of the signaling mechanism between 
LPS, IL-33 and MMP-9 (highlighted in dashed arrows in Figure 4.1). Also, though we 
have a functional endpoint to our animal study, we have not been able to establish an 
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anatomical or mechanistic endpoint. We observed that sST2 prevent cardiac dysfunction 
but could not answer how after picrosirius heart staining produced non-significant results.  
Despite substantial research completed with animal sepsis models with 
breakthrough finding, it has produced disappointing results in clinical trials [23, 26].  
Mice cannot accurately simulate clinical sepsis for various reasons. For one, mice of the 
same age and weight are inbred and do not have the varying comorbidities of people, 
which contribute significantly to patient outcome. In addition, clinical sepsis arises from 
various infectious sources such as pneumonia and abdominal infection which may have 
an impact on the magnitude of response to infection. There are also differences at the 
molecular level since mice and human are different species. For example, in humans, C-
reactive protein (CRP) is known activate the complement system in inflammatory 
situations whereas in the rat, it does not [117, 118]. However, the use of animal model 
still allows investigators to look into fundamental pathological processes that may help us 
understand clinical cases. Also, it allows for much larger sample size, control of 
confounding variables and is relatively inexpensive. 
In conclusion, this study demonstrated IL-33 inhibition reduced the myocardial 
dysfunction in FIP treated mice. Combined results from cellular and animal studies point 
to induction of IL-33 expression in the myocardium and that IL-33 regulates MMP-9 
response in cardiomyocytes.  
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Figure 4.1. Schematic diagram of the hypothetical mechanism in the LPS/IL-33 
signaling pathway in cardiomyocyte. 
 
This study demonstrated IL-33 inhibition reduced the myocardial dysfunction in FIP 
treated mice. FIP induces IL-33 expression in the myocardium and IL-33 regulates the 
MMP-9 response in cardiomyocytes. The signaling pathways indicated by dashed arrows 
have not been confirmed in this study but a proposed mechanism that remains to be 
investigated in future studies. 
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Although cardiac dysfunction was observed using a functional study, the 
morphology of the diseased heart could not be observed due to limited resources. Septic 
heart has been reported to go through reversible dilation of ventricular walls [6, 119]. It 
would be interesting to see if IL-33 levels correlate with ventricular dilation and if it can 
be prevented by sST2 treatment.  
Also, though we could not observe quantitative changes in myocardial collagen, 
various cardiac pathologies where MMPs are involved have disorganization of the 
collagen network rather than an absolute change in content [120]. It would be interesting 
to study the structural organization of the collagen network of the myocardium using 
scanning electron microscopy.  
To further confirm our experimental findings it would be interesting to repeat the 
experiments with a CLP sepsis model. The scope of our study was limited to looking at 
cardiac function; however, the next step will require addressing the signaling pathways 
between LPS, IL-33 and MMP-9 and also, look at other organs commonly affected 
during sepsis. 
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